Your browser doesn't support javascript.
Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.
Yan, Haiyan; Sun, Jing; Wang, Kun; Wang, Huiqiang; Wu, Shuo; Bao, Linlin; He, Weiqing; Wang, Dong; Zhu, Airu; Zhang, Tian; Gao, Rongmei; Dong, Biao; Li, Jianrui; Yang, Lu; Zhong, Ming; Lv, Qi; Qin, Feifei; Zhuang, Zhen; Huang, Xiaofang; Yang, Xinyi; Li, Yuhuan; Che, Yongsheng; Jiang, Jiandong.
  • Yan H; CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Sun J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
  • Wang K; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Wang H; CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Wu S; CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Bao L; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • He W; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Wang D; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi 117004, China.
  • Zhu A; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
  • Zhang T; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Gao R; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Dong B; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Li J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Yang L; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Zhong M; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Lv Q; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Qin F; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Zhuang Z; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
  • Huang X; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
  • Yang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Li Y; CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Che Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
  • Jiang J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing 100050, China.
Acta Pharm Sin B ; 11(9): 2850-2858, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1415197
Semantic information from SemMedBD (by NLM)
1. Antiviral Agents NEG_TREATS COVID-19
Subject
Antiviral Agents
Predicate
NEG_TREATS
Object
COVID-19
2. Macrolide Antibiotics DISRUPTS Cytopathogenic Effec
Subject
Macrolide Antibiotics
Predicate
DISRUPTS
Object
Cytopathogenic Effec
3. Cells LOCATION_OF Viral Proteins
Subject
Cells
Predicate
LOCATION_OF
Object
Viral Proteins
4. Antiviral Agents NEG_TREATS COVID-19
Subject
Antiviral Agents
Predicate
NEG_TREATS
Object
COVID-19
5. Macrolide Antibiotics DISRUPTS Cytopathogenic Effect, Viral
Subject
Macrolide Antibiotics
Predicate
DISRUPTS
Object
Cytopathogenic Effect, Viral
6. Cells LOCATION_OF Viral Proteins
Subject
Cells
Predicate
LOCATION_OF
Object
Viral Proteins
ABSTRACT
COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Acta Pharm Sin B Year: 2021 Document Type: Article Affiliation country: J.apsb.2021.02.024

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Acta Pharm Sin B Year: 2021 Document Type: Article Affiliation country: J.apsb.2021.02.024